21 studies found for:    CD44
Show Display Options
Rank Status Study
1 Completed A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Condition: Neoplasms
Intervention: Drug: RO5429083
2 Unknown  Methylation Status of CD44 Promoter Region in Primary Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention:
3 Completed Vascular Access for Hemodialysis and Inflammation
Condition: Vascular Access for Hemodialysis and Inflammation
Intervention:
4 Active, not recruiting Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Conditions: Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: vismodegib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
5 Withdrawn Prognostic Value of Stem Cell Related Markers
Condition: Breast Cancer
Intervention:
6 Recruiting Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   CLL;   SLL
Intervention: Drug: A6
7 Recruiting Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Condition: Lung Cancer
Intervention: Procedure: phlebotomy
8 Active, not recruiting Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Intervention: Drug: Paclitaxel+Reparixin
9 Completed Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
Conditions: HER2-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Recruiting GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Conditions: Neoplasms, Oral;   Mouth Neoplasms
Intervention: Drug: GSK1120212
11 Enrolling by invitation Effects of ADSC Therapy in Women With POF
Condition: Premature Ovarian Failure
Intervention: Procedure: Autologous fat grafting
12 Active, not recruiting Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Simvastatin
13 Completed Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557
Condition: Asthma
Interventions: Drug: GSK2269557;   Drug: GSK2269557 matching placebo
14 Active, not recruiting Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
Condition: Oral Cavity Cancer
Intervention: Drug: PF-00299804/Placebo
15 Unknown  Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids
Condition: Cortico Atrophy
Interventions: Drug: RV3391A;   Drug: Placebo
16 Active, not recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
17 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
18 Terminated RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
19 Completed Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Disseminated Neuroblastoma;   Malignant Neoplasm;   Ovarian Choriocarcinoma;   Ovarian Embryonal Carcinoma;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Mixed Germ Cell Tumor;   Ovarian Monodermal and Highly Specialized Teratoma;   Ovarian Polyembryoma;   Ovarian Yolk Sac Tumor;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Neuroblastoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage II Ovarian Epithelial Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Multiple Myeloma;   Stage III Ovarian Epithelial Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer;   Testicular Choriocarcinoma;   Testicular Choriocarcinoma and Embryonal Carcinoma;   Testicular Choriocarcinoma and Seminoma;   Testicular Choriocarcinoma and Teratoma;   Testicular Choriocarcinoma and Yolk Sac Tumor;   Testicular Embryonal Carcinoma;   Testicular Embryonal Carcinoma and Seminoma;   Testicular Embryonal Carcinoma and Teratoma;   Testicular Embryonal Carcinoma and Teratoma With Seminoma;   Testicular Embryonal Carcinoma and Yolk Sac Tumor;   Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma;   Testicular Teratoma;   Testicular Yolk Sac Tumor;   Testicular Yolk Sac Tumor and Teratoma;   Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions: Drug: ipilimumab;   Drug: therapeutic allogeneic lymphocytes
20 Enrolling by invitation Stem Cell Transplantation for the Treatment of Knee Osteoarthritis
Condition: Knee Osteoarthritis
Intervention: Biological: Autologous Stem Cell Transplantation

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years